NEURODEGENERATIVE DISEASES
Clinical trials for NEURODEGENERATIVE DISEASES explained in plain language.
Never miss a new study
Get alerted when new NEURODEGENERATIVE DISEASES trials appear
Sign up with your email to follow new studies for NEURODEGENERATIVE DISEASES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Alzheimer's drug extension trial halted early — what we know
Disease control TerminatedThis study gave Alzheimer's patients who had already completed earlier XPro1595 trials an extra 55 to 74 weeks of the drug to check long-term safety and effects on memory and brain health. Only 11 people took part, and the trial was terminated early, so the findings are limited. …
Matched conditions: NEURODEGENERATIVE DISEASES
Phase: PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Neurodegenerative drug study ends early after only 17 participants
Disease control TerminatedThis study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could …
Matched conditions: NEURODEGENERATIVE DISEASES
Phase: PHASE3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC